Community pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocol

Table 2 Measurement scheme

	Instrument	T0	T1	T2
Baseline measures
Socio-demographics	Questionnaire	X
Psychiatric diagnosis	SCID-I	X
Chronic physical conditions	Check list	X
Effect evaluation
Compliance	Medication intake percentage	Continuous registration
Compliance	MAQ		X	X
Severity of depression	PHQ-9	X	X	X
Health-related quality of life	EuroQOL-5D	X	X	X
Anxiety (state)	STAI-S	X	X	X
Side-effects	Check-list		X	X
Satisfaction	Armando PD questionnaire		X	X
Economic evaluation
Direct and indirect costs	CSRI – adapted	X	X	X

T0 = Baseline, T1 = 3 months after baseline, T2 = 6 months after baseline.
SCID-I: Structured Clinical Interview Axis I DSM-IV; MAQ: Medication Adherence questionnaire; PHQ-9: Patient Health Questionnaire 9-item depression module; EuroQOL-5D: European Quality of Life Scale – 5 domains; STAI-S: State-Trait Anxiety Inventory (State subscale); CSRI: Client Service Receipt Inventory.

ISSN: 1471-2458